Amyloid β 1-42 (Aβ 1-42 ), total tau (t-tau), and phosphorylated tau (p-tau) are the main cerebrospinal fluid (CSF) biomarkers for early diagnosis of Alzheimer's disease (AD). Detection of AD is critically important in view of the growing number of potential new drugs that may influence the course of the disease in its early phases. However, cut-off levels for these CSF biomarkers have not yet been established. Variability in absolute concentrations of AD biomarkers is high among studies and significant differences were noticed even within the same datasets. Variability in biomarkers levels in these assays may be due to many aspects of operating procedures. Standardization of pre-analytical and analytical procedures in collection, treatment, and storage of CSF samples is crucial because differences in sample handling can drastically influence results. Multicenter studies showed that usage of ELISA kits from different manufacturers also affects outcome. So far only very few studies tested the efficiency of ELISA kits produced by different vendors. In this study, the performance of Innogenetics (Gent, Belgium) and Invitrogen (Camarillo, CA, USA) ELISA kits for t-tau and Aβ 1-42 was tested. Passing-Bablok analysis showed significant differences between Invitrogen and Innogenetics ELISA methods, making it impossible to use them interchangeably. 
Introduction
Alzheimer's disease (AD) is the major primary cause of dementia. Ferri and collaborators estimated that 24 million people suffered from dementia in 2005, with this number reaching 81 million by 2040 [1] . Clinical diagnosis of AD, which is still based on symptomatology, is accurate in only 63 to 90% of dementia cases [2] . A growing number of potential treatments for AD are in different phases of preclinical and clinical research and thus much effort is dedicated to identify reliable biomarkers to enable an accurate diagnosis of AD.
Three main cerebrospinal fluid (CSF) biomarkers of AD, amyloid β (Aβ ), total tau (t-tau), and phosphorylated forms of tau (p-tau) reflect two major neuropathological hallmarks of AD -neurofibrillary tangles and senile plaques [3] . These CSF biomarkers are altered in early stages of AD, even before the occurrence of the first dementia symptoms, and permit to differentiate patients with prodromal AD (i.e. those with mild cognitive impairment, MCI) who often progress to AD, from healthy controls [4, 5] . CSF biomarkers are also used for differentiation of AD from other primary causes of dementia, such as vascular dementia, frontotemporal dementia (FTD), and dementia with Lewy bodies [6] [7] [8] [9] [10] . Reduction of Aβ in CSF of AD patients is explained by Aβ 1-42 aggregation into senile plaques, increase of t-tau reflects neuronal degeneration, while elevation of p-tau is a consequence of neurofibrillary degeneration and consequent tangles formation in the brain [11] [12] [13] . Although numerous studies in which diagnostic accuracy of CSF biomarkers was analyzed have been published, an ideal biomarker (with specificity and sensitivity over 85%) could not yet be defined.
High variability in concentrations of CSF biomarkers is observed among different centers and laboratories [14] [15] [16] . Causes of variations could be either due to pre-analytical and analytical factors or differences in ELISA kits from various manufacturers. Pre-analytical procedures refer to selection of research participants, CSF sampling and treatment, sample storage (temperature, tube type), and freeze/thaw cycles [7, 17] 
Results
Demographic data of all patient groups including HC are presented in Table 1 . T-tau and Aβ 1-42 CSF concentrations obtained by both Innogenetics and Invitrogen ELISA kits are summarized in Table 2 and Figure 1 , and Table 3 and 
Discussion
Our Innogenetics kits indicate that this assumption cannot be applied for either t-tau ( Figure 3A) or Aβ 1-42 ( Figure 3B ). Thus, these two methods for determination of t-tau and Aβ were only determined on samples of AD patients. Data are presented as mean ± SD and median (25th-75th percentile).
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Innogenetics Aβ 1 In the study of Bjerke et al. [26] it was reported that centrifugation affects a number of CSF proteins, while Vanderstichele et al. [17] did not confirm this. It is considered that variations in protein levels due to centrifugation are found only in hemorrhagic samples, urging
Vanderstichele et al. [17] to recommend centrifugation of hemorrhagic samples only.
Although centrifugation speed does not affect levels of proteins it is generally recommended to centrifuge 10 min at 2,000 g at room temperature [27] . Applying Innogenetics ELISA kit, higher t-tau and Aβ 1-42 values were obtained than using the Invitrogen ELISA kit (Table 2 ). This fact was already noted by Fialova and collaborators [28] .
Only a few other studies compared results of ELISA kits from different vendors [5, 12, 29] , and the efficiency of Innogenetics and Invitrogen [14] . The goal of multi-center studies is standardization of procedures for determination of AD CSF biomarkers and establishment of cut-off levels. However, despite numerous studies, consensus criteria for cut-off levels are not yet set and thus vary considerably among studies [15, 32, 35] .
Beside early diagnostics of AD, determination of CSF biomarkers is necessary for monitoring of potential treatments. It is generally accepted that immunization using Aβ, the use of β-and γ-secretase inhibitors, and GSK3β inhibitors, which are currently among the most promising disease-modifying therapies, should be applied in the early stages of disease when neurodegeneration is not in an advanced stage [38] . Therefore, future studies are still required to (i) determine cut-off levels for Aβ , t-tau, and p-tau; (ii) standardize pre-analytical procedures across laboratories to account for inter-center variability (for review see [17] ; and The authors declare no conflict of interest.
